Sudarshan Pharma rises 7% after shifting to NSE main board
In short
Sudarshan Pharma shares jumped 7% on Wednesday after the company moved from BSE’s SME platform to the NSE main board. Its board is also set to review Q2 FY27 results and a possible fundraising plan on October 29.
This matters because a main-board listing can change how investors view the stock. The report does not say how much money the company may raise or what the Q2 numbers will show.
What the reporting says
Sudarshan Pharma shares rose 7% on Wednesday after the company migrated from BSE’s SME platform to the NSE main board, according to a Mint Markets summary. The board is also scheduled to review Q2 FY27 results and a potential fundraising proposal on October 29. The snippet does not state the size or terms of any fundraising, nor does it explain the full reason behind the share move beyond the listing change.
Why it matters
Sudarshan Pharma shares rose 7% on Wednesday after the company migrated from BSE’s SME platform to the NSE main board. The board is scheduled to review Q2 FY27 results and a possible fundraising proposal on October 29. The reporting does not state the fundraising amount or whether the results will be strong or weak, so the next catalyst remains uncertain.